Detection of the Epstein-Barr Virus and DNA-Topoisomerase II-α in Recurrent and Nonrecurrent Giant Cell Lesion of the Jawbones
Table 2
Mean values of Topo II-α in relation to clinical parameters in central giant cell lesion of jawbones.
Variable
Total no. (%)
Topo II-α a
value
Topo II-α b
value
Age (y)
<30
8 (61.5%)
1.49 ± 0.63
0.273
8.00 ± 7.89
0.716
≥30
5 (38.5%)
1.09 ± 1.01
NS
7.00 ± 6.57
NS
Sex
Male
3 (23.1%)
0.75 ± 0.17
0.001
8.12 ± 2.77
0.021
Female
10 (76.9%)
1.71 ± 0.87
*S
15.24 ± 4.64
*S
Site
Maxilla
5 (38.5%)
1.70 ± 0.84
0.001
5.69 ± 2.00
0.001
Mandible
8 (61.5%)
2.50 ± 0.14
*S
8.16 ± 0.88
*S
Clinical behavior
Nonrecurrent
8 (61.5%)
1.15 ± 0.11
0.002
5.67 ± 2.01
0.001
Recurrent
5 (38.5%)
2.07 ± 0.95
*S
8.17 ± 0.87
*S
MGCs: multinucleated giant cells; MSCs: mononuclear stromal cells.
aMean ± standard deviation of Topo II-α in MGCs.
bMean ± standard deviation of Topo II-α in MSCs. -test. NS: not significant.
*S: significant.
